1 2 3 4 5	Curtis G. Hoke (State Bar No. 282465) Timothy Litzenburg (appearance pro hac vice) Michael J. Miller (appearance pro hac vice) THE MILLER FIRM, LLC 108 Railroad Ave. Orange, VA 22960 Telephone: (540) 672-4224 Facsimile: (540) 672-3055 choke@millerfirmllc.com tlitzenburg@millerfirmllc.com mmiller@millerfirmllc.com	ELECTRONICALLY FILED Superior Court of Californi County of San Francisco 06/07/2018 Clerk of the Court BY:VANESSA WU Deputy Cle
7	Attorneys for Plaintiff DEWAYNE JOHNSON	
8 9 10		E STATE OF CALIFORNIA AN FRANCISCO
11 12	Dwayne Johnson) Case No. CGC-16-550128
13	Plaintiff, vs.	PLAINTIFF'S OPPOSITION TO MONSANTO'S MOTION IN LIMINE NO. 16 TO EXCLUDE EVIDENCE,
15	Monsanto Company	 ARGUMENT, OR REFERENCE TO TRACE IMPURITIES IN ROUNDUP PRO® OR RANGEPRO®
16	Defendant	Trial Judge: TBD
18 19		Trial Date: June 18, 2018 Time: 9:30 a.m.
20		_) Department: TBD
22		
23		
24		
26		
27 28		
20		

PLAINTIFF'S OPPOSITION TO MONSANTO'S MOTION IN LIMINE NO. 16

INTRODUCTION

Monsanto seeks to exclude any evidence, argument, or reference to trace impurities in the Roundup formulation—impurities that contributed to Mr. Johnson's cancer—because, according to Monsanto, the formulation has been approved by the EPA and, thus, must be safe as a matter of law. This argument is meritless. If pushed to its logical extreme, Plaintiff would be precluded from presenting *any* evidence that Roundup causes cancer just because the product has been approved by the EPA—an argument this Court has already rejected. Put simply, the Roundup's impurities are relevant for several reasons, notwithstanding the fact that the formulation has received EPA approval, which, as discussed below, was obtained because Monsanto withheld from the agency important information regarding Roundup's toxicological profile. Plaintiff has uncovered a trove of evidence indicating that the impurities in Roundup's formulation contribute to the product's carcinogenicity and that Monsanto has long been aware of such facts. All such evidence goes to the heart of causation and should be presented to the trier of fact.

ARGUMENT

Evidence is relevant if it has a "tendency in reason to prove or disprove any disputed fact of consequence to the determination of the action..." Cal. Evid. Code § 210 (emphasis added); People v. Nelson (2008) 43 Cal.4th 1242, 1266; Donlen v. Ford Motor Company (2013) 217 Cal.App.4th 138, 148 as modified on denial of reh'g (July 8, 2013). Moreover, section 352 "speaks in terms of undue prejudice. Unless the dangers of undue prejudice, confusion, or time consumption 'substantially outweigh' the probative value of relevant evidence, a section 352 objection should fail." People v. Scott (2011) 52 Cal.4th 452, 490–491 (emphasis in original) (quoting People v. Cudjo (1993) 6 Cal.4th 585, 609); People v. Yu (1983) 143 Cal.App.3d 358, 377 (when applying Section 352, "prejudicial" is not synonymous with "damaging.").

(a) EPA Approval of Roundup is no Bar to Evidence Regarding Impurities in Roundup Formulation

As an initial matter, Monsanto's argument that Plaintiff should be precluded from presenting any evidence regarding Roundup's impurities just because the EPA has approved the Roundup formulation is meritless. As this Court has held regarding Monsanto's preemption argument:

Under the express terms of the statute, EPA approval of a pesticide is *not* a defense for the commission of any offense under FIFRA, it is just prima facie evidence that the pesticide and its labeling and packaging are compliant with FIFRA and, accordingly, any state law that imposes labeling requirements consistent with FIFRA is not preempted...Monsanto's conflict preemption argument as to the design defect claims fails for the same reason as its conflict preemption argument as to the failure to warn claims.

Ex. A to Hoke Decl., Sargon Order at 42-43 (emphasis in original). The same logic applies here. Just because the EPA has approved the Roundup formulation does not preclude Plaintiff from presenting evidence regarding the individual components of the formulation which contribute to Roundup's carcinogenicity. Regulatory approval provides no shield to central issues of causation, especially since Plaintiff also contends that Monsanto misled the EPA regarding the safety of Roundup's formulation (as discussed below).

(b) Evidence of Monsanto's Knowledge that Roundup Contains Carcinogenic Impurities is Relevant

Monsanto is well aware that Roundup formulations contain carcinogenic impurities, such as formaldehyde. Indeed, in 2015, Dr. William Heydens, lead toxicologist for Monsanto, identified the "[I]ow level presence of formaldehyde (*carcinogenic by inhalation*) in Roundup." Ex. B to Hoke Decl., MONGLY00990361 (emphasis added). Moreover, Dr. Heydens also noted the "presence of NNG (N-nitroso-glyphosate) in Roundup - many N-Nitroso compounds are carcinogenic." *Id.* NNG is formed when glyphosate interacts with nitrites in Roundup formulations, the environment or in the human body. Ex. E to Hoke Decl., MONGLY00925905 at *2 ("concern has been expressed over the possibility that glyphosate could react with nitrite in the diet to form N- Nitrosophosphonomethyl glycine (NPMG), a

putative carcinogen."). NNG is part of a family of carcinogenic chemicals called nitroso compounds. Nitroso compounds that have been tested have consistently been shown to be carcinogenic. Loh, et al. *N-nitroso compounds and cancer incidence: the European Prospective Investigation into Cancer and Nutrition (EPIC)–Norfolk Study,* AM J CLIN NUTR MAY 2011, vol. 93 no. 5 1053-061. The EPA initially required that Monsanto test for the carcinogenicity of NNG in the 1970s and early 1980s. The testing for NNG by Monsanto was mainly conducted by IBT laboratories which was shut down in the 1970s due to fraud. The EPA determined that these NNG studies were not acceptable to show that NNG was not mutagenic. Ex. F to Hoke Decl, MONGLY01298438 at 2-3.

The EPA, however, did not require additional testing on NNG provided that Monsanto keep the levels of NNG below 1 ppm. *Id.* Before getting a pass from the EPA, Monsanto did conduct one long-term carcinogenicity test of NNG in mice outside of IBT laboratories. This study demonstrated a statistically significant increase in malignant lymphomas in male mice. Ex. G to Hoke Decl., MONGLY04272196 at *1-4. There is no evidence that Monsanto ever submitted this study to the EPA. The evidence at trial will also show that NNG levels in glyphosate can exceed 1 ppm and that NNG levels increase the longer glyphosate is stored.

1, 4 Dioxane is another impurity in the Roundup formulation which has been associated with cancer. Indeed, the substance is a known carcinogen to the State of California. *See https://oehha.ca.gov/proposition-65/chemicals/14-dioxane*. Reference to 1, 4 Dioxane will not be found on the Roundup label. Monsanto downplays the existence of 1,4-dioxane precisely because of its carcinogenicity. Ex. H to Hoke Decl., MONGLY01041300 at *1 ("The other thing is that we have to be very careful before we go slinging mud about 1,4-dioxane in Chinese glyphosate in public, because whether it is 1 ppm or 10 ppm, we most likely have it on our products too, and the general public does not understand the difference between 1 ppm and a bucket full...if there is a chemical that is considered to be a cancer-causing, it don't matter how much is in there, just that it is in there!")

Importantly, two of Plaintiff's experts address the issue of Roundup's impurities such as NNG and 1, 4 Dioxane: Dr. Benbrook from the regulatory perspective and Dr. Sawyer's toxicological opinions. *See* Ex. I to Hoke Decl., Benbrook Expert Report at 55-56; Ex. J to Hoke Decl., Sawyer Expert Report at 76-77. Given that Roundup's carcinogenicity is a central issue of this litigation, evidence regarding the impurities which Plaintiff contends contribute to the carcinogenicity of Roundup (and of which Monsanto was aware) are directly relevant. *Kelly v. New West Federal Savings* (1996) 49 Cal.App.4th 659, 674 (the trial court cannot "exclude evidence which is *directly relevant to the primary issues of the litigation...*"). Monsanto's contentions that the level of impurities in Roundup are not carcinogenic or below the regulatory safe limit go to the *weight* of Plaintiff's evidence to the contrary, not admissibility. *People v. Solomon* (2010) 49 Cal.4th 792, 818 ("[i]t is the jury, not the reviewing court, that resolves conflicts in the evidence.").

Monsanto's assertion that such evidence should be excluded because "impurities are not approved separately from the GBF as a whole" is a red herring. Monsanto MIL No. 16 at 3. Surfactants are also part of the "approved" Roundup formulation, but nothing precludes Plaintiff from arguing that surfactants contribute to the carcinogenicity of the formulated product used by Mr. Johnson. Impurities are no different. As discussed above, Monsanto was well aware of the carcinogenic potential of such impurities and provided incomplete information to the EPA regarding Roundup's impurities, all issues that go to the heart of causation.

The jury should be provided with comprehensive evidence of Roundup's chemical profile, assisted with the proper expert evidence, in order to resolve the central disputes of this case. *People v. Jones* (2013) 57 Cal.4th 899, 948, *as modified on denial of reh'g* (Oct. 2, 2013) (quoting (*People v. Tran* (2011) 51 Cal.4th 1040, 1047) (evidence can only be excluded if it poses an "an *intolerable 'risk* to the fairness of the proceedings or the reliability of the outcome"). Lastly, given that Monsanto will undoubtedly present evidence in support of the ostensible safety of Roundup and its history of regulatory approval, Plaintiff should be

- 1	11	
1	permitted to introduce evidence, such as that discussed above, to the contrary for rebuttal	
2	purposes. <i>People v. Nunez</i> (2013) 57 Cal.4th 1, 27 ("Rebuttal evidence is relevant and thus	
3	admissible if it 'tend[s] to disprove a fact of consequence on which the defendant has	
4	introduced evidence."").	
5		CONCLUSION
6	For the foregoing reasons, the Court should deny Monsanto's Motion <i>in limine</i> No. 1	
7	and permit Plaintiff to present argument, evidence and reference to impurities in the Roundu	
8	formulation that caused Plaintiff's cancer.	
9		
10	DATED: June 7, 2018	Respectfully submitted,
11		By: /s/ Curtis G. Hoke
12		Curtis G. Hoke (SBN 282465)
14		Timothy Litzenburg (appearance <i>pro hac vice</i>) Michael J. Miller (appearance <i>pro hac vice</i>)
15		THE MILLER FIRM, LLC 108 Railroad Ave.
16		Orange, VA 22960 (540) 672-4224 phone
17		(540) 672-3055 fax
18		choke@millerfirmllc.com tlitzenburg@millerfirmllc.com
19		mmiller@millerfirmllc.com
20		Attorneys for Plaintiff
21		
22		
23		
24		
25		
26		
27		
28		